Table 1.

Baseline characteristics

	Regorafenib (N=100)
		Male, n (%)	58 (58)
Age, years
Median (range)	56.5 (31–78)
≥65 years, n (%)	22 (22)
ECOG PS, n (%)
0	59 (59)
1	41 (41)
Time from initial diagnosis to treatment assignment
Median (range), months	33.6 (7.4–138.1)
<18 months, n (%)	11 (11)
≥18 months, n (%)	89 (89)
Time from diagnosis of metastatic disease to treatment assignment
Median (range), months	29.3 (6.9–138.1)
<18 months, n (%)	17 (17)
≥18 months, n (%)	83 (83)
Primary site of disease, n (%)
Colon	55 (55)
Rectum	24 (24)
Colon and rectum	21 (21)
KRAS status, n (%)
Wild-type	43 (43)
Mutant	53 (53)
Unknown	4 (4)
BRAF status, n (%)
Wild-type	6 (6)
Mutant	0
Unknown	94 (94)
Brain metastases, n (%)
No	77 (77)
Yes	2 (2)
Unknown	21 (21)
Liver metastases, n (%)
No	22 (22)
Yes	78 (78)

ECOG PS, Eastern Cooperative Oncology Group performance status.